Oxcarbazepine and hyponatremia [2]

American Journal of Health-System Pharmacy

Volumn 59, Issue 5, 2002, Pages 467-

  Woster, Patricia ^a   Carrazana, Enrique J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; DIURETIC AGENT; OXCARBAZEPINE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; HYPONATREMIA; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; AGE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; NOTE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CARBAMAZEPINE; HUMANS; HYPONATREMIA; MIDDLE AGED; RISK FACTORS;

EID: 0036500538     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.5.467a     Document Type: Letter

References (4)

1. Hyponatremia and leukopenia associated with oxcarbazepine following carbamazepine therapy
2. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review
3. Oxcarbazepine (Trileptal) effect on serum sodium